BNTX vs. GILD, MRNA, BIIB, ARGX, NBIX, QGEN, RGEN, PCVX, RVMD, and EXEL
Should you be buying BioNTech stock or one of its competitors? The main competitors of BioNTech include Gilead Sciences (GILD), Moderna (MRNA), Biogen (BIIB), argenx (ARGX), Neurocrine Biosciences (NBIX), Qiagen (QGEN), Repligen (RGEN), Vaxcyte (PCVX), Revolution Medicines (RVMD), and Exelixis (EXEL). These companies are all part of the "biological products, except diagnostic" industry.
Gilead Sciences (NASDAQ:GILD) and BioNTech (NASDAQ:BNTX) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, community ranking, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.
Gilead Sciences presently has a consensus target price of $83.69, suggesting a potential upside of 30.21%. BioNTech has a consensus target price of $111.70, suggesting a potential upside of 11.03%. Given BioNTech's stronger consensus rating and higher probable upside, research analysts clearly believe Gilead Sciences is more favorable than BioNTech.
Gilead Sciences has higher revenue and earnings than BioNTech. Gilead Sciences is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.
BioNTech has a net margin of 4.01% compared to BioNTech's net margin of 1.76%. BioNTech's return on equity of 24.34% beat Gilead Sciences' return on equity.
83.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 0.2% of Gilead Sciences shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Gilead Sciences had 9 more articles in the media than BioNTech. MarketBeat recorded 27 mentions for Gilead Sciences and 18 mentions for BioNTech. Gilead Sciences' average media sentiment score of 0.95 beat BioNTech's score of 0.25 indicating that BioNTech is being referred to more favorably in the news media.
Gilead Sciences received 2332 more outperform votes than BioNTech when rated by MarketBeat users. Likewise, 77.37% of users gave Gilead Sciences an outperform vote while only 42.80% of users gave BioNTech an outperform vote.
Gilead Sciences has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500. Comparatively, BioNTech has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500.
Summary
Gilead Sciences beats BioNTech on 11 of the 18 factors compared between the two stocks.
Get BioNTech News Delivered to You Automatically
Sign up to receive the latest news and ratings for BNTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
BioNTech Competitors List
Related Companies and Tools